Liu Xinyan, Wu Na, Al-Mureish Abdulrahman
Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Clinical Skills Practice Teaching Center, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Int J Gen Med. 2021 Mar 30;14:1155-1165. doi: 10.2147/IJGM.S296316. eCollection 2021.
Glycosylated hemoglobin (HbA1C) and glycated albumin (GA) can be used for blood glucose management of a person with diabetes as a result of their convenience and stability. However, there is no corresponding standard for the application of glycosylated hemoglobin and glycosylated albumin in gestational diabetes mellitus (GDM). In this review, we summarize the published research and discuss three aspects of the significance of HBA1C and GA in GDM patients: screening of gestational diabetes mellitus, blood glucose monitoring and the relationship with pregnancy outcome. At present, studies suggest that HBA1C can be used as a screening indicator for pregnant women, but it cannot completely replace OGTT. HbA1C and GA can be used for blood glucose management in patients with GDM to reduce the incidence of GDM complications. However, the application of HBA1C and GA in GDM still needs more research and clinical practice support.
糖化血红蛋白（HbA1C）和糖化白蛋白（GA）因其便利性和稳定性，可用于糖尿病患者的血糖管理。然而，糖化血红蛋白和糖化白蛋白在妊娠期糖尿病（GDM）中的应用尚无相应标准。在本综述中，我们总结了已发表的研究，并讨论了HbA1C和GA在GDM患者中的三个重要方面：妊娠期糖尿病的筛查、血糖监测以及与妊娠结局的关系。目前，研究表明HbA1C可作为孕妇的筛查指标，但不能完全替代口服葡萄糖耐量试验（OGTT）。HbA1C和GA可用于GDM患者的血糖管理，以降低GDM并发症的发生率。然而，HbA1C和GA在GDM中的应用仍需要更多的研究和临床实践支持。
